The last 20 years delivered ups and downs to long-term care (LTC) pharmacies that caused significant disruption
in the M&A space. Strategic players swept across the nation, gobbling up small and middle-market businesses in order
to gain market dominance. CMS underwent several rounds of updates to their reimbursement plans that either
accelerated or decelerated the rate of consolidation. PBMs continue their stronghold as opaque middlemen,
controlling drug prices through complex negotiations and burden some pharmacies with complex contracts
and DIR fees1
. The US economy experienced the greatest economic downturn since the great depression,
followed by a decade of incredible recovery that was fortified by quantitative easing, technology, job creation and a
swelling demographic. With so much momentum in the broader economy, it appears the record healthcare and
pharmacy deal activity will continue roaring into 2020, for now.